Dr. Chang Yi Wang

Employing UBI Pharma’s solid protein drug development technologies and world-class manufacturing capability, we are aggressively developing high entry barrier products such as long-acting protein drugs (Biobetters) and specialty injectables. We believe that our exclusive technology platforms combined with the medical and research resources in Taiwan will lead us to the global market as one of the top players in the pharmaceutical and biotechnology industry. While achieving our goals and maximizing the dividend to our shareholders, we are responsible for abiding by the law, cultivating biotechnology talents, and creating job opportunities. Our first priority will always be to address the unmet medical needs of mankind, offering innovative, affordable, and high quality pharmaceuticals that improve quality of life of the patients.